Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cormedix (CRMD)
NASDAQ:CRMD
Holding CRMD?
Track your performance easily
CRMD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.57 - $7.41
Previous Close$7.25
Volume896.36K
Average Volume (3M)681.61K
Market Cap
$404.71M
Enterprise Value$359.69M
Total Cash (Recent Filing)$45.61M
Total Debt (Recent Filing)$594.00K
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Nov 07, 2024EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding55,859,964
10 Day Avg. Volume1,067,001
30 Day Avg. Volume681,610
Standard Deviation0.23
R-Squared0.13
Alpha0.00142
Financial Highlights & Ratios
Price to Book (P/B)8.73
Price to Sales (P/S)499.62
Price to Cash Flow (P/CF)-7.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue446.20
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-6.63
Forecast
1Y Price Target
$12.60Price Target Upside73.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Cormedix News
PremiumPress Releases
CorMedix Inc. Announces New Commercial Agreement
Bulls Say, Bears Say
Bulls Say
Commercial AgreementsThe company has entered into a 5-year commercial supply agreement for DefenCath with ARC Dialysis, LLC, which is seen as a strong commercial start for DefenCath.
Market ExpansionThe expansion to TPN market and its ~5MM infusions/year (or ~10MM vials/yr) would represent a meaningful label expansion to DefenCath.
Sales GrowthDefenCath initial launch appears strong and gives confidence in accelerating growth in coming quarters.
Bears Say
Regulatory ApprovalsUpdates on the outpatient launch and a J-Code and TDAPA application are still under review by CMS.
Research And Development ExpensesIt's unclear if those expectations will be moved out to 2025 given additional R&D expenses earmarked for TPN trials and the pediatric study.
Sales GrowthCRMD remains a 'show me story' where sustained DefenCath quarterly sales growth will be needed to drive a sustained value inflection.
---
Ownership Overview
10.25% Insiders
8.42% Mutual Funds
13.02% Other Institutional Investors
68.31% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRMD FAQ
What was Cormedix’s price range in the past 12 months?
Cormedix lowest stock price was $2.57 and its highest was $7.41 in the past 12 months.
What is Cormedix’s market cap?
Currently, no data Available
When is Cormedix’s upcoming earnings report date?
Cormedix’s upcoming earnings report date is Nov 07, 2024 which is in 49 days.
How were Cormedix’s earnings last quarter?
Cormedix released its earnings results on Aug 14, 2024. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.251 by $0.001.
Is Cormedix overvalued?
According to Wall Street analysts Cormedix’s price is currently Undervalued.
Does Cormedix pay dividends?
Cormedix does not currently pay dividends.
What is Cormedix’s EPS estimate?
Cormedix’s EPS estimate is -$0.12.
How many shares outstanding does Cormedix have?
Cormedix has 55,859,962 shares outstanding.
What happened to Cormedix’s price movement after its last earnings report?
Cormedix reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.251. Following the earnings report the stock price went up 30.159%.
Which hedge fund is a major shareholder of Cormedix?
Among the largest hedge funds holding Cormedix’s share is Elliott Investment Management LP. It holds Cormedix’s shares valued at 7M.
---
Cormedix Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.60 (73.91% Upside)
$12.60 (73.91% Upside)
Blogger Sentiment
Bullish
CRMD Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
93.20%
12-Months-Change
Fundamentals
Return on Equity
-111.55%
Trailing 12-Months
Asset Growth
1.22%
Trailing 12-Months
Company Description
Cormedix
CorMedix, Inc. operates as a pharmaceutical and medical device company, which seeks to in-license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.
---
CRMD Earnings Call
Q2 2024
0:00 / 0:00
---
CRMD Stock 12 Month Forecast
Average Price Target
$12.60
▲(73.91% Upside)
Technical Analysis
Best Analysts Covering CRMD
1 Year
1 Year Success Rate
11/17 ratings generated profit
1 Year Average Return
+29.67%
reiterated a buy rating last month
Copying Serge Belanger's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +29.67% per trade.
---